chlormezanone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	603	80-77-3

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clormezanone
chlormezanone
chlormethazanone
chlormethazone
dichloromezanone
phenarol
dl-Chlormezanone

A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.

Molecular weight: 273.73
Formula: C11H12ClNO3S
CLOGP: 1.57
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 54.45
ALOGS: -2.23
ROTB: 1

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	2.50 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
May 20, 1960	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Temperature regulation disorder	674.74	127.25	137	3731	5995	63479159
Food allergy	590.09	127.25	137	3731	11264	63473890
Coeliac disease	563.95	127.25	135	3733	12662	63472492
Immunodeficiency	511.88	127.25	137	3731	20117	63465037
Bursitis	426.03	127.25	136	3732	36905	63448249
Rash erythematous	411.62	127.25	137	3731	42373	63442781
Fluid retention	366.14	127.25	137	3731	59549	63425605
Upper respiratory tract infection	320.52	127.25	136	3732	81911	63403243
Hyperhidrosis	294.09	127.25	139	3729	107697	63377457
Asthma	263.18	127.25	136	3732	127425	63357729
Erythema	230.20	127.25	139	3729	175612	63309542
Hepatic enzyme increased	207.29	127.25	137	3731	202191	63282963
Constipation	187.14	127.25	134	3734	224809	63260345
Back pain	176.59	127.25	138	3730	264007	63221147
Hypersensitivity	166.20	127.25	139	3729	292546	63192608
Rheumatoid arthritis	163.96	127.25	130	3738	253689	63231465
Drug hypersensitivity	154.93	127.25	137	3731	310550	63174604
Prescribed overdose	130.85	127.25	56	3812	34097	63451057

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Temperature regulation disorder	683.16	170.48	131	3510	5722	79735025
Food allergy	602.84	170.48	131	3510	10693	79730054
Coeliac disease	591.07	170.48	130	3511	11221	79729526
Immunodeficiency	511.80	170.48	131	3510	21637	79719110
Bursitis	447.08	170.48	131	3510	35713	79705034
Rash erythematous	393.42	170.48	133	3508	57636	79683111
Fluid retention	361.26	170.48	131	3510	69678	79671069
Upper respiratory tract infection	323.75	170.48	130	3511	91038	79649709
Asthma	274.56	170.48	130	3511	134965	79605782
Hyperhidrosis	266.34	170.48	132	3509	151360	79589387
Hepatic enzyme increased	240.26	170.48	131	3510	182479	79558268
Erythema	226.12	170.48	135	3506	223155	79517592
Rheumatoid arthritis	208.26	170.48	125	3516	208345	79532402
Hypersensitivity	203.68	170.48	134	3507	262105	79478642
Constipation	184.94	170.48	130	3511	282920	79457827
Back pain	181.06	170.48	132	3509	304048	79436699
Drug hypersensitivity	180.84	170.48	131	3510	298785	79441962

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M03BB02	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives
ATC	M03BB52	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives
ATC	M03BB72	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:51371	muscle relaxants
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009125	Muscle Relaxants, Central
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Anxiety	indication	48694002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4018260	VUID
N0000146590	NUI
D00268	KEGG_DRUG
2373	RXNORM
4018260	VANDF
C0008223	UMLSCUI
CHEBI:3619	CHEBI
CHEMBL1200714	ChEMBL_ID
DB01178	DRUGBANK_ID
D002720	MESH_DESCRIPTOR_UI
2717	PUBCHEM_CID
7323	IUPHAR_LIGAND_ID
782	INN_ID
GP568V9G19	UNII
4413	MMSL
d00909	MMSL
001447	NDDF
387400008	SNOMEDCT_US
71634000	SNOMEDCT_US

Pharmaceutical products:

None